

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/96 (08-03)

Approved for use through 07/31/2006 0MB 0651-0031

STATEMENT UNDER 37 CFR 3.73(b)

6213.200-US

Applicant/Patent Owner:	Lundbeck et al.
Application No./Patent No.:	09/870,884
Entitled: GLUCOSE DEPENDENT RELEASE OF INSULIN FROM GLUCOSE SENSING INSULIN DERIVATIVES	
Novo Nordisk® A/S	a Corporation
(Name of Assignee)	(Type of Assignee, e.g. corporation, partnership, university, government, agency, etc.)

states that it is:

1. X the assignee of the entire right, title, and interest; or
 2. an assignee of less than the entire right, title and interest

The extent (by percentage) of its ownership interest is _____ % in the patent application/patent identified above by virtue of either:

A. [X] An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 012108, Frame 0132, or for which a copy thereof is attached.

OR

B. [] A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:


1. From:	To:
The document was recorded in the United States Patent and Trademark Office at	
Reel:	Frame: , or for which a copy thereof is attached.
2. From:	To:
The document was recorded in the United States Patent and Trademark Office at	
Reel:	Frame: , or for which a copy thereof is attached.
3. From:	To:
The document was recorded in the United States Patent and Trademark Office at	
Reel:	Frame: , or for which a copy thereof is attached.

Additional documents in the chain of title are listed on a supplemental sheet.

Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e. the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Date	Ole F. Ramsby Typed or printed name
609-987-5800	 Signature
Telephone number	Senior Vice President, General Counsel Title

This collection of information is required by 37 CFR 3.73 (b). The information is required to obtain or retain a benefit by the public which is to tie (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 114. This collection is estimated to take 12 minutes to complete, including gathering, preparing and submitting the completed application form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, US Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**POWER OF ATTORNEY FOR PATENT APPLICATION ASSIGNEE AND****Attorney's Docket
Number:
6213.200-US**

As an individual who is authorized to act on behalf of the assignee of the entire right and title to this patent application entitled:

Title: **GLUCOSE DEPENDENT RELEASE OF INSULIN FROM GLUCOSE SENSING
INSULIN DERIVATIVES**

The specification of which (check only one item below):

- [] is attached hereto
[X] was filed as United States application


Application No. **09/870,884**

POWER OF ATTORNEY: As a named assignee, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. Reza Green, Reg. No. 38,475; Richard W. Bork, Reg. No. 36,459; Marc A. Began, Reg. No. 48,829; Rosemarie R. Wilk-Orescan, Reg. No. 45,220; Len S. Smith, Reg. No. 43,139

Send Correspondence to: Reza Green, Esq.
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 0840

Direct Telephone Calls To:
Reza Green
(609) 987-5800

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Name of Assignee: Ole F. Ramsby	Title: Senior Vice President, General Counsel	Address: Novo Nordisk A/S Novo Alle Bagsvaerd, Denmark 2880
Signature of Assignee: 	Date: Feb. 27th, 2004	